JPWO2023201332A5 - - Google Patents

Info

Publication number
JPWO2023201332A5
JPWO2023201332A5 JP2024560675A JP2024560675A JPWO2023201332A5 JP WO2023201332 A5 JPWO2023201332 A5 JP WO2023201332A5 JP 2024560675 A JP2024560675 A JP 2024560675A JP 2024560675 A JP2024560675 A JP 2024560675A JP WO2023201332 A5 JPWO2023201332 A5 JP WO2023201332A5
Authority
JP
Japan
Prior art keywords
composition
use according
weeks
target
administration period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512468A (ja
JP2025512468A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065774 external-priority patent/WO2023201332A1/en
Publication of JP2025512468A publication Critical patent/JP2025512468A/ja
Publication of JPWO2023201332A5 publication Critical patent/JPWO2023201332A5/ja
Publication of JP2025512468A5 publication Critical patent/JP2025512468A5/ja
Pending legal-status Critical Current

Links

JP2024560675A 2022-04-15 2023-04-14 筋緊張性ジストロフィーを処置するための筋標的化複合体の投薬 Pending JP2025512468A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263331733P 2022-04-15 2022-04-15
US63/331,733 2022-04-15
US202263368691P 2022-07-18 2022-07-18
US63/368,691 2022-07-18
PCT/US2023/065774 WO2023201332A1 (en) 2022-04-15 2023-04-14 Dosing of muscle targeting complexes for treating myotonic dystrophy

Publications (3)

Publication Number Publication Date
JP2025512468A JP2025512468A (ja) 2025-04-17
JPWO2023201332A5 true JPWO2023201332A5 (https=) 2026-04-23
JP2025512468A5 JP2025512468A5 (https=) 2026-04-23

Family

ID=88330392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560675A Pending JP2025512468A (ja) 2022-04-15 2023-04-14 筋緊張性ジストロフィーを処置するための筋標的化複合体の投薬

Country Status (10)

Country Link
US (1) US20250249117A1 (https=)
EP (1) EP4508092A1 (https=)
JP (1) JP2025512468A (https=)
KR (1) KR20250004771A (https=)
CN (1) CN119343373A (https=)
AU (1) AU2023252927A1 (https=)
CA (1) CA3248684A1 (https=)
IL (1) IL316206A (https=)
MX (1) MX2024012730A (https=)
WO (1) WO2023201332A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312067B2 (en) * 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
AU2021318851A1 (en) * 2020-07-23 2023-03-16 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Similar Documents

Publication Publication Date Title
IL316206A (en) Dosage of muscle targeting complexes for the treatment of myotonic dystrophy
IL316143A (en) Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
IL309936A (en) Muscle targeting complexes and formulations for the treatment of dystrophinopathy
IL311507A (en) Dosing of muscle targeting complexes for the treatment of dystrophinopathy
IL309910A (en) Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
IL315944A (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
ES2593304T3 (es) Conjugados de transportador derivado de caliqueamicina
JP2024160045A5 (https=)
JPWO2021142307A5 (https=)
JPWO2023201332A5 (https=)
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
KR20250099717A (ko) 근육 표적화 복합체 및 dmd 유전자의 엑손 45를 스키핑하기 위한 그의 용도
JP2025528797A (ja) トランスフェリン受容体結合タンパク質及びコンジュゲート
JPWO2021142234A5 (https=)
JPWO2023044398A5 (https=)
JPWO2022026152A5 (https=)
JPWO2022147209A5 (https=)
JPWO2021154476A5 (https=)
JPWO2023283615A5 (https=)
JPWO2023201324A5 (https=)
WO2025137547A1 (en) Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy
JPWO2022271543A5 (https=)
JPWO2023283613A5 (https=)
JPWO2022147207A5 (https=)
JPWO2023077120A5 (https=)